Smoking behaviour in European patients with established coronary heart disease
Open Access
- 6 October 2005
- journal article
- research article
- Published by Oxford University Press (OUP) in European Heart Journal
- Vol. 27 (1) , 35-41
- https://doi.org/10.1093/eurheartj/ehi497
Abstract
Aims Treatment guidelines for patients with established coronary disease emphasize the importance of smoking cessation. We aimed to study smoking behaviour in European patients, as well as trends in this behaviour over time. We further aimed to evaluate the relation between selected patient characteristics and smoking cessation. Methods and results We studied patients who were enrolled in the second European Action on Secondary Prevention through Intervention to Reduce Events (EUROASPIRE) survey, which was undertaken in 15 European countries during 1999–2000. Consecutive patients, ≤70 years were identified after coronary artery bypass grafting, percutaneous transluminal coronary angioplasty, admission for myocardial infarction, or admission for myocardial ischaemia. Patients were then interviewed, at a median of 1.5 years after the index event. During the interview, data were collected on a broad range of clinical characteristics, including smoking status, which was validated by breath carbon monoxide levels. The prevalence of smoking was compared with data from the first EUROASPIRE survey, which had a similar design, and was conducted during 1995–96. In EUROASPIRE II, 5551 patients attended the interview and 1172 (21%) were (persistent) smokers. No decrease in smoking prevalence was observed similar to the first survey (19%). The proportion of smokers was 39% in patients aged Conclusion The prevalence of smoking in European patients with established coronary disease is too high: one out of each five patients smokes, despite a personal advice to stop. Thus, still there is a need for the development of effective smoking cessation programmes.Keywords
This publication has 24 references indexed in Scilit:
- European guidelines on cardiovascular disease prevention in clinical practice Third Joint Task Force of European and other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of eight societies and by invited experts)European Heart Journal, 2003
- Long-Term Results After the Glycoprotein IIb/IIIa Inhibitor Abciximab in Unstable AnginaCirculation, 2003
- Effect of glycoprotein IIb/IIIa receptor blocker abciximab on outcome in patients with acute coronary syndromes without early coronary revascularisation: the GUSTO IV-ACS randomised trialThe Lancet, 2001
- Reperfusion therapy for acute myocardial infarction with fibrinolytic therapy or combination reduced fibrinolytic therapy and platelet glycoprotein IIb/IIIa inhibition: the GUSTO V randomised trialThe Lancet, 2001
- Lifestyle and risk factor management and use of drug therapies in coronary patients from 15 countries. Principal results from EUROASPIRE II Euro Heart Survey ProgrammeEuropean Heart Journal, 2001
- Clinical reality of coronary prevention guidelines: a comparison of EUROASPIRE I and II in nine countriesThe Lancet, 2001
- Registration and management of smoking behaviour in patients with coronary heart disease. The EUROASPIRE surveyPublished by Oxford University Press (OUP) ,1999
- Cigarette Smoking and Mortality RiskArchives of internal medicine (1960), 1999
- Prevention of coronary heart disease in clinical practice Recommendations of the Second Joint Task Force of European and other Societies on Coronary PreventionEuropean Heart Journal, 1998
- EUROASPIRE: A European Society of Cardiology survey of secondary prevention of coronary heart disease: Principal resultsEuropean Heart Journal, 1997